Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). (Q38384261)
Jump to navigation
Jump to search
scientific article published on 13 January 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). |
scientific article published on 13 January 2009 |
Statements
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) (English)
Fabio Ciceri
Orietta Spinelli
Massimo Bernardi
Renato Bassan
Elena Oldani
Tamara Intermesoli
Manuela Tosi
Barbara Peruta
Erika Borlenghi
Enrico M Pogliani
Elisabetta Terruzzi
Pietro Fabris
Vincenzo Cassibba
Giorgio Lambertenghi-Deliliers
Giacomo Gianfaldoni
Andrea Gallamini
Eros Di Bona
Claudio Romani
Anna Maria Scattolin
Tiziano Barbui
Alessandro Rambaldi
13 January 2009